-11- Exhibit IN2 MEDFIELD PHARMACEUTICALS Analysis of Fleximat Reformulation (in millions of U.S. dollars, unless otherwise noted) 2011 2012 2013 2014 2015 2016 2017 2018 Incremental Research 35 35 Incremental Marketing 25 25 25 25 25 Growth 296 -509% 296 29% 296 29% 296 New Sales 214.77 219.07 109.53 111.72 113.96 116.24 120.93 Marginal Sales 118.56 0.00 0.00 0.00 56.96 86.58 116.24 118.56 120.93 New Cost of Sales 49.40 50.39 25.19 25.70 26.21 26.73 27.27 27.81 Marginal Cost of Sales 0.00 0.00 0_00 13.10 19.91 26.73 27.27 27.81 New Direct Marketing 57.99 59.15 29.57 30.17 30.77 31.38 32 01 32.65 Old Direct Marketing 57.99 59.15 29.57 14.79 7.39 0.00 0.00 0.00 Marginal Direct Marketing 0.00 0.00 0.00 15.38 23.38 31.38 32 01 32.65 New G&A 8.59 8.76 4.38 4.47 4.56 4.65 4.74 4.84 Old G&A 8.59 8.76 4.38 2.19 1.10 0.00 0.00 0.00 Marginal G&A 0.00 0.00 0.00 2.28 3.46 4.65 4 74 4.84 Marginal Cash Flow Pretax (60.00) (60.00) (25.00) 1.20 14.82 53.47 54.54 Marginal NOPAT 55.63 (40.80) (40.80) (17.00) 0.82 10.08 36.36 37.09 37.83 NPV 49.56 Note: Only the first eight years are shown